Key actors in cancer therapy: epigenetic modifiers
Key actors in cancer therapy: epigenetic modifiers
Epigenetic reprogramming plays a crucial role in the tumorigenicity and maintenance of tumor-specific gene expression thatespecially occurs through DNA methylation and/or histone modifications. It has well-defined mechanisms. It is known that alterationsin the DNA methylation pattern and/or the loss of specific histone acetylation/methylation markers are related to several hallmarks ofcancer, such as drug resistance, stemness, epithelial–mesenchymal transition, and metastasis. It has also recently been highlighted thatepigenetic alterations are critical for the regulation of the stemlike properties of cancer cells (tumor-initiating cells; cancer stem cells).Cancer stem cells are thought to be responsible for the recurrence of cancer which makes the patient return to the clinic with metastatictumor tissue. Hence, the dysregulation of epigenetic machinery represents potential new therapeutic targets. Therefore, compounds withepigenetic activities have become crucial for developing new therapy regimens (e.g., antimetastatic agents) in the fight against cancer.Here, we review the epigenetic modifiers that have already been used in the clinic and/or in clinical trials, related preclinical studies incancer therapy, and the smart combination strategies that target cancer stem cells along with the other cancer cells. The emerging role ofepitranscriptome (RNA epigenetic) in cancer therapy has also been included in this review as a new avenue and potential target for thebetter management of cancer-beneficial epigenetic machinery
___
- Annunziato A (2008). DNA packaging: nucleosomes and chromatin.
Nature Education 1 (1): 26.
- Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M et al. (2014).
Therapeutic targeting of BET bromodomain proteins in
castration-resistant prostate cancer. Nature 510 (7504): 278-282.
- Azad N S, El-Khoueiry A, Yin J, Oberg AL, Flynn P et al. (2017).
Combination epigenetic therapy in metastatic colorectal cancer
(mCRC) with subcutaneous 5-azacitidine and entinostat: a
phase 2 consortium/stand up 2 cancer study. Oncotarget 8
(21): 35326.
- Aztopal N, Erkisa M, Ari F, Dere E, Ulukaya E (2018a). Dual
inhibition of Wnt/beta-catenin signaling and histone
deacetylation as a new strategy to eliminate breast cancer stem
cells by augmentation of apoptosis. In FEBS Open Bio (Vol. 8).
Hoboken, NJ, USA: Wiley. pp. 301-301.
- Aztopal N, Erkisa M, Erturk E, Ulukaya E, Tokullugil AH, Ari F
(2018b). Valproic acid, a histone deacetylase inhibitor, induces
apoptosis in breast cancer stem cells. Chemico-Biological
Interactions 280: 51-58.
- Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E et al.
(2009). Epigenetic regulation of CD133 and tumorigenicity of
CD133+ ovarian cancer cells. Oncogene 28 (2): 209-218.
- Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O et
al. (2006). EZH2 expression is associated with high proliferation
rate and aggressive tumor subgroups in cutaneous melanoma
and cancers of the endometrium, prostate, and breast. Journal
of Clinical Oncology 24 (2): 268-273.
- Bannister AJ, Kouzarides T (2011). Regulation of chromatin by
histone modifications. Cell Research 21 (3): 381-395.
Baylin SB (2005). DNA methylation and gene silencing in cancer.
Nature Reviews Clinical Oncology 2 (S1), S4.
- Bernstein BE, Meissner A, Lander ES (2007). The mammalian
epigenome. Cell 128 (4): 669-681.
- Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ et al. (2006).
A bivalent chromatin structure marks key developmental genes
in embryonic stem cells. Cell 125 (2): 315-326.
- Bird A (2002). DNA methylation patterns and epigenetic memory.
Genes & Development 16 (1): 6-21.
- Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C,
Kumar AJ et al. (2008). Phase II trial of the histone deacetylase
inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic
acid, SAHA) in patients with recurrent and/or metastatic head
and neck cancer. Investigational New Drugs 26 (1): 81-87.
- Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K (2006).
Genome-wide mapping of Polycomb target genes unravels
their roles in cell fate transitions. Genes & Development 20 (9):
1123-1136.
- Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM
et al. (2008). Phase I study of epigenetic modulation with
5-azacytidine and valproic acid in patients with advanced
cancers. Clinical Cancer Research 14 (19): 6296-6301.
- Brueckner B, Boy RG, Siedlecki P, Musch T, Kliem HC et al. (2005).
Epigenetic reactivation of tumor suppressor genes by a novel
small-molecule inhibitor of human DNA methyltransferases.
Cancer Research 65 (14): 6305-6311.
- Budden T, van der Westhuizen A, Bowden NA (2018). Sequential
decitabine and carboplatin treatment increases the DNA repair
protein XPC, increases apoptosis and decreases proliferation in
melanoma. BMC Cancer 18 (1): 100.
- Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke‐Puranik Y et al.
(2014). A therapeutic trial of decitabine and vorinostat in
combination with chemotherapy for relapsed/refractory acute
lymphoblastic leukemia. American Journal of Hematology 89
(9): 889-895.
- Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G (2007).
Valproic acid enhances tubulin acetylation and apoptotic
activity of paclitaxel on anaplastic thyroid cancer cell lines.
Endocrine-Related Cancer 14 (3): 839-845.
- Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD et al.
(2006). Valproic acid inhibits invasiveness in bladder cancer
but not in prostate cancer cells. Journal of Pharmacology and
Experimental Therapeutics 319 (2): 533-542.
- Chen Y, Wang XQ, Zhang Q, Zhu JY, Li Y et al. (2017).
(−)-Epigallocatechin-3-gallate inhibits colorectal cancer stem
cells by suppressing wnt/β-catenin pathway. Nutrients 9 (6):
572.
- Chikamatsu K, Ishii H, Murata T, Sakakura K, Shino M et al. (2013).
Alteration of cancer stem cell‐like phenotype by histone
deacetylase inhibitors in squamous cell carcinoma of the head
and neck. Cancer Science 104 (11): 1468-1475.
- Christman JK (2002). 5-Azacytidine and 5-aza-2′-deoxycytidine as
inhibitors of DNA methylation: mechanistic studies and their
implications for cancer therapy. Oncogene 21 (35): 5483-5495.
- Chung SS, Vadgama JV (2015). Curcumin and epigallocatechin
gallate inhibit the cancer stem cell phenotype via downregulation of STAT3–NFκB signaling. Anticancer Research 35
(1): 39-46.
- Cipro Š, Hřebačková J, Hraběta J, Poljaková J, Eckschlager T (2012).
Valproic acid overcomes hypoxia-induced resistance to
apoptosis. Oncology Reports 27 (4): 1219-1226.
- Clermont PL, Fornaro L, Crea F (2017). Elevated expression of a
pharmacologic Polycomb signature predicts poor prognosis in
gastric and breast cancer. Epigenomics 9 (10): 1329-1335.
- Cui Q, Shi H, Ye P, Li L, Qu Q et al. (2017). m6A RNA methylation
regulates the self-renewal and tumorigenesis of glioblastoma
stem cells. Cell Reports 18 (11): 2622-2634.
- da Motta LL, Ledaki I, Purshouse K, Haider S, De Bastiani MA et
al. (2017). The BET inhibitor JQ1 selectively impairs tumour
response to hypoxia and downregulates CA9 and angiogenesis
in triple negative breast cancer. Oncogene 36 (1): 122-132.
- Desrosiers R, Friderici K, Rottman F (1974). Identification of
methylated nucleosides in messenger RNA from Novikoff
hepatoma cells. Proceedings of the National Academy of
Sciences 71 (10): 3971-3975.
- Easwaran H, Tsai HC, Baylin SB (2014). Cancer epigenetics: tumor
heterogeneity, plasticity of stem-like states, and drug resistance.
Molecular Cell 54 (5): 716-727.
- Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017). Histone
deacetylase inhibitors as anticancer drugs. International
Journal of Molecular Sciences 18 (7): 1414.
- Falkenberg KJ, Johnstone RW (2014). Histone deacetylases and
their inhibitors in cancer, neurological diseases and immune
disorders. Nature Reviews Drug Discovery 13 (9): 673-691.
- Fang F, Balch C, Schilder J, Breen T, Zhang S et al. (2010). A phase
1 and pharmacodynamic study of decitabine in combination
with carboplatin in patients with recurrent, platinum‐resistant,
epithelial ovarian cancer. Cancer 116 (17): 4043-4053.
- Fang F, Munck J, Tang J, Taverna P, Wang Y et al. (2014). The novel,
small-molecule DNA methylation inhibitor SGI-110 as an
ovarian cancer chemosensitizer. Clinical Cancer Research 20
(24): 6504-6516.
- Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB et al. (2010).
Selective inhibition of BET bromodomains. Nature 468 (7327):
1067-1073.
- Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J et
al. (2005). Loss of acetylation at Lys16 and trimethylation at
Lys20 of histone H4 is a common hallmark of human cancer.
Nature Genetics 37 (4): 391-400.
- Fustin JM, Doi M, Yamaguchi Y, Hida H, Nishimura S et al. (2013).
RNA-methylation-dependent RNA processing controls the
speed of the circadian clock. Cell, 155 (4): 793-806.
- Gailhouste L, Liew LC, Hatada I, Nakagama H, Ochiya T (2018).
Epigenetic reprogramming using 5-azacytidine promotes an
anti-cancer response in pancreatic adenocarcinoma cells. Cell
Death & Disease 9 (5): 468.
- Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H et al. (2015).
Phase 1 study of romidepsin plus erlotinib in advanced nonsmall cell lung cancer. Lung Cancer 90 (3): 534-541.
- Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol
N et al. (2015). m6A mRNA methylation facilitates resolution
of naïve pluripotency toward differentiation. Science 347
(6225): 1002-1006.
- Grabarska A, Łuszczki JJ, Nowosadzka E, Gumbarewicz E,
Jeleniewicz W et al. (2017). Histone deacetylase inhibitor
SAHA as potential targeted therapy agent for larynx cancer
cells. Journal of Cancer 8 (1): 19-28.
- Guo Y, Shu L, Zhang C, Su ZY, Kong ANT (2015). Curcumin inhibits
anchorage-independent growth of HT29 human colon cancer
cells by targeting epigenetic restoration of the tumor suppressor
gene DLEC1. Biochemical Pharmacology 94 (2): 69-78.
- Haberland M, Montgomery RL, Olson EN (2009). The many roles
of histone deacetylases in development and physiology:
implications for disease and therapy. Nature Reviews Genetics
10 (1): 32-42.
- Haigentz Jr M, Kim M, Sarta C, Lin J, Keresztes RS et al. (2012).
Phase II trial of the histone deacetylase inhibitor romidepsin in
patients with recurrent/metastatic head and neck cancer. Oral
Oncology 48 (12): 1281-1288.
- Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE et al. (2004).
Upregulation and nuclear recruitment of HDAC1 in hormone
refractory prostate cancer. The Prostate 59 (2): 177-189.
- Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C et al.
(2010). Type‐specific roles of histone deacetylase (HDAC)
overexpression in ovarian carcinoma: HDAC1 enhances
cell proliferation and HDAC3 stimulates cell migration with
downregulation of E‐cadherin. International Journal of Cancer
127 (6): 1332-1346.
- Herceg Z (2007). Epigenetics and cancer: towards an evaluation of
the impact of environmental and dietary factors. Mutagenesis
22 (2): 91-103.
- Hosokawa M, Tanaka S, Ueda K, Iwakawa S (2017). Different
Schedule-Dependent Effects of Epigenetic Modifiers on
Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
Biological and Pharmaceutical Bulletin: b17-00439.
- Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T et al. (2006).
Epigenetic regulation of the expression of the novel stem cell
marker CDCP1 in cancer cells. The Journal of Pathology: A
Journal of the Pathological Society of Great Britain and Ireland
210 (1): 75-84.
- Issa JPJ, Kantarjian HM (2009). Targeting DNA methylation. Clinical
Cancer Research 15 (12): 3938-3946.
- James MI, Iwuji C, Irving G, Karmokar A, Higgins JA (2015).
Curcumin inhibits cancer stem cell phenotypes in ex vivo
models of colorectal liver metastases, and is clinically safe and
tolerable in combination with FOLFOX chemotherapy. Cancer
Letters 364 (2): 135-141.
- Jenuwein T, Allis CD (2001). Translating the histone code. Science
293 (5532): 1074-1080.
- Jiang P, Xu C, Chen L, Chen A, Wu X et al. (2018). Epigallocatechin‐3‐
gallate inhibited cancer stem cell–like properties by targeting
hsa‐mir‐485‐5p/RXRα in lung cancer. Journal of Cellular
Biochemistry 119 (10): 8623-8635.
- Jones PA, Baylin SB (2007). The epigenomics of cancer. Cell 128 (4):
683-692.
Jones PA, Issa JPJ, Baylin S (2016). Targeting the cancer epigenome
for therapy. Nature Reviews Genetics 17 (10): 630-641.
- Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M et al.
(2011). Combination epigenetic therapy has efficacy in patients
with refractory advanced non–small cell lung cancer. Cancer
Discovery 1 (7): 598-607.
- Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB et al. (2015). Epigenetic
therapy for solid tumors: from bench science to clinical trials.
Epigenomics 7 (2): 215-235.
- Kagara N, Huynh KT, Kuo C, Okano H, Sim MS et al. (2012).
Epigenetic regulation of cancer stem cell genes in triplenegative breast cancer. The American Journal of Pathology 181
(1): 257-267.
- Kantarjian H, Issa JPJ, Rosenfeld CS, Bennett JM, Albitar M
et al. (2006). Decitabine improves patient outcomes in
myelodysplastic syndromes. Cancer 106 (8): 1794-1803.
- Kemp CD, Rao M, Xi S, Inchauste S, Mani H et al. (2012). Polycomb
repressor complex-2 is a novel target for mesothelioma therapy.
Clinical Cancer Research 18 (1): 77-90.
- Khan GN, Kim EJ, Shin TS, Lee SH (2017). Azacytidine-induced
chemosensitivity to doxorubicin in human breast cancer
MCF7 Cells. Anticancer Research 37 (5): 2355-2364.
- Kim SJ, Amankwah E, Connors S, Park HY, Rincon M et al. (2014).
Safety and chemopreventive effect of Polyphenon E in
preventing early and metastatic progression of prostate cancer
in TRAMP mice. Cancer Prevention Research 7 (4): 435-444.
- Kleer CG, Cao Q, Varambally S, Shen R, Ota I et al. (2003). EZH2 is
a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proceedings of the
National Academy of Sciences 100 (20): 11606-11611.
- Klose RJ, Bird AP (2006). Genomic DNA methylation: the mark and
its mediators. Trends in Biochemical Sciences 31 (2): 89-97.
- Kondo Y, Shen L, Ahmed S, Boumber Y, Sekido Y et al. (2008).
Downregulation of histone H3 lysine 9 methyltransferase G9a
induces centrosome disruption and chromosome instability in
cancer cells. PloS One 3 (4): e2037.
- Kornblith AB, Herndon JE, Silverman LR, Demakos EP, OdchimarReissig R et al. (2002). Impact of azacytidine on the quality
of life of patients with myelodysplastic syndrome treated in a
randomized phase III trial: a Cancer and Leukemia Group B
study. Journal of Clinical Oncology 20 (10): 2441-2452.
- Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S et al.
(2015). A phase 2 study of concurrent radiation therapy,
temozolomide, and the histone deacetylase inhibitor valproic
acid for patients with glioblastoma. International Journal of
Radiation Oncology* Biology* Physics 92 (5): 986-992.
- Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N (2015).
Guadecitabine (SGI‐110) priming sensitizes hepatocellular
carcinoma cells to oxaliplatin. Molecular Oncology 9 (9): 1799-
1814.
- Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B et al.
(2005). Results of a phase 2 study of valproic acid alone or in
combination with all-trans retinoic acid in 75 patients with
myelodysplastic syndrome and relapsed or refractory acute
myeloid leukemia. Annals of Hematology 84 (1): 61-66.
- Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB et al. (2017).
Bromodomain inhibitors, JQ1 and I-BET 762, as potential
therapies for pancreatic cancer. Cancer Letters 394: 76-87.
- Lee DH, Qi J, Bradner JE, Said JW, Doan NB (2015a). Synergistic effect
of JQ 1 and rapamycin for treatment of human osteosarcoma.
International Journal of Cancer 136 (9): 2055-2064.
- Lee TG, Jeong EH, Kim SY, Kim HR, Kim CH (2015b). The
combination of irreversible EGFR TKI s and SAHA induces
apoptosis and autophagy‐mediated cell death to overcome
acquired resistance in EGFR T 790 M‐mutated lung cancer.
International Journal of Cancer 136 (11): 2717-2729.
- Lee WY, Chen PC, Wu WS, Wu HC, Lan CH et al. (2017).
Panobinostat sensitizes KRAS‐mutant non‐small‐cell lung
cancer to gefitinib by targeting TAZ. International Journal of
Cancer 141 (9): 1921-1931.
- Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RWC et
al. (2014). Immune regulation by low doses of the DNA
methyltransferase inhibitor 5-azacitidine in common human
epithelial cancers. Oncotarget 5 (3): 587-598.
- Li LH, Zhang PR, Cai PY, Li C (2016). Histone deacetylase inhibitor,
Romidepsin (FK228) inhibits endometrial cancer cell growth
through augmentation of p53-p21 pathway. Biomedicine &
Pharmacotherapy 82: 161-166.
- Li SY, Sun R, Wang HX, Shen S, Liu Y et al. (2015). Combination
therapy with epigenetic-targeted and chemotherapeutic drugs
delivered by nanoparticles to enhance the chemotherapy
response and overcome resistance by breast cancer stem cells.
Journal of Controlled Release 205: 7-14.
- Li X, Tang J, Huang W, Wang F, Li P et al. (2017). The M6A
methyltransferase METTL3: acting as a tumor suppressor in
renal cell carcinoma. Oncotarget 8 (56): 96103-96116.
- Li Z, Wang Y, Qiu J, Li Q, Yuan C et al. (2013). The polycomb group
protein EZH2 is a novel therapeutic target in tongue cancer.
Oncotarget 4 (12): 2532-2549.
- Liu CC, Lin JH, Hsu TW, Su K, Li AFY et al. (2015). IL‐6 enriched
lung cancer stem‐like cell population by inhibition of cell cycle
regulators via DNMT1 upregulation. International Journal of
Cancer 136 (3): 547-559.
- Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S et al. (2009). Curcumin is
a potent DNA hypomethylation agent. Bioorganic & Medicinal
Chemistry Letters 19 (3): 706-709.
- Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E et
al. (2011). Schedule-dependent synergy of histone deacetylase
inhibitors with DNA damaging agents in small cell lung cancer.
Cell Cycle 10 (18): 3119-3128.
- Luu TH, Morgan RJ, Leong L, Lim D, McNamara M et al. (2008). A
phase II trial of vorinostat (suberoylanilide hydroxamic acid)
in metastatic breast cancer: a California Cancer Consortium
study. Clinical Cancer Research 14 (21): 7138-7142.
- Matei D, Fang F, Shen C, Schilder J, Arnold A et al. (2012). Epigenetic
resensitization to platinum in ovarian cancer. Cancer Research
72 (9): 2197-2205.
- Medeiros BC, McCaul K, Kambhampati S, Pollyea DA, Kumar R
et al. (2018). Randomized study of continuous high-dose
lenalidomide, sequential azacitidine and lenalidomide, or
azacitidine in persons 65 years and over with newly-diagnosed
acute myeloid leukemia. Haematologica 103 (1): 101-106.
- Meissner A (2010). Epigenetic modifications in pluripotent and
differentiated cells. Nature Biotechnology 28 (10): 1079-1088.
- Min A, Im SA, Kim DK, Song SH, Kim HJ et al. (2015). Histone
deacetylase inhibitor, suberoylanilide hydroxamic acid
(SAHA), enhances anti-tumor effects of the poly (ADP-ribose)
polymerase (PARP) inhibitor olaparib in triple-negative breast
cancer cells. Breast Cancer Research 17 (1): 33.
- Modesitt SC, Sill M, Hoffman JS, Bender DP (2008). A phase II
study of vorinostat in the treatment of persistent or recurrent
epithelial ovarian or primary peritoneal carcinoma: a
Gynecologic Oncology Group study. Gynecologic Oncology
109 (2): 182-186.
- Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH et
al. (2006). Aggresome disruption: a novel strategy to enhance
bortezomib-induced apoptosis in pancreatic cancer cells.
Cancer Research 66 (7): 3773-3781.
- Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC et
al. (2002). Histone H3-lysine 9 methylation is associated with
aberrant gene silencing in cancer cells and is rapidly reversed
by 5-aza-2′-deoxycytidine. Cancer Research 62 (22): 6456-
6461.
- Nishizawa Y, Konno M, Asai A, Koseki J, Kawamoto K et al. (2018).
Oncogene c-Myc promotes epitranscriptome m6A reader
YTHDF1 expression in colorectal cancer. Oncotarget 9 (7):
7476-7486.
- Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y et al.
(2008). Successful treatment of anaplastic thyroid carcinoma
with a combination of oral valproic acid, chemotherapy,
radiation and surgery. Endocrine Journal: 0812020217-
0812020217. 245-249
- Noh JH, Eun JW, Ryu SY, Jeong KW, Kim JK et al. (2006). Increased
expression of histone deacetylase 2 is found in human
hepatocellular carcinoma. Molecular and Cellular Toxicology
2 (3): 166-169.
- O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P et al.
(2015). Belinostat in patients with relapsed or refractory
peripheral T-cell lymphoma: results of the pivotal phase II
BELIEF (CLN-19) study. Journal of Clinical Oncology 33 (23):
2492-2499
- O’Connor OA, Özcan M, Jacobsen ED, Vidal JMR, Trotman J et al.
(2015). First multicenter, randomized phase 3 study in patients
(Pts) with relapsed/refractory (R/R) peripheral T-cell lymphoma
(PTCL): Alisertib (MLN8237) versus investigator’s choice
(Lumiere trial; NCT01482962). Blood 126 (23): 341. 12-13
- Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM et al. (2007).
Phase IIb multicenter trial of vorinostat in patients with
persistent, progressive, or treatment refractory cutaneous
T-cell lymphoma. Journal of Clinical Oncology 25 (21): 3109-
3115.
- Ong PS, Wang L, Chia DMH, Seah JYX, Kong LR et al. (2016). A
novel combinatorial strategy using Seliciclib® and Belinostat®
for eradication of non-small cell lung cancer via apoptosis
induction and BID activation. Cancer Letters 381 (1): 49-57.
- Pérez-Salvia M, Esteller M (2017). Bromodomain inhibitors and
cancer therapy: From structures to applications. Epigenetics 12
(5): 323-339.
- Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL et al. (2009). Phase
II multi-institutional trial of the histone deacetylase inhibitor
romidepsin as monotherapy for patients with cutaneous T-cell
lymphoma. Journal of Clinical Oncology 27 (32): 5410-5417.
- Popis MC, Blanco S, Frye M (2016). Post-transcriptional methylation
of transfer and ribosomal RNA in stress response pathways,
cell differentiation and cancer. Current Opinion in Oncology
28 (1): 65-71.
- Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS et
al. (2008). Activity of the histone deacetylase inhibitor
belinostat (PXD101) in preclinical models of prostate cancer.
International Journal of Cancer 122 (6): 1400-1410.
- Raffoux E, Cras A, Recher C, Boëlle PY, de Labarthe A et al. (2010).
Phase 2 clinical trial of 5-azacitidine, valproic acid, and alltrans retinoic acid in patients with high-risk acute myeloid
leukemia or myelodysplastic syndrome. Oncotarget 1(1): 34-
42.
- Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA et
al. (2016). Panobinostat plus bortezomib and dexamethasone
in previously treated multiple myeloma: outcomes by prior
treatment. Blood 127 (6): 713-721.
- Saletore Y, Meyer K, Korlach J, Vilfan ID, Jaffrey S, Mason CE (2012).
The birth of the Epitranscriptome: deciphering the function
of RNA modifications. Genome Biology 13 (10): 175. doi:
10.1186/gb-2012-13-10-175
- Samavat H, Newman AR, Wang R, Yuan JM, Wu AH et al. (2016).
Effects of green tea catechin extract on serum lipids in
postmenopausal women: a randomized, placebo-controlled
clinical trial. The American Journal of Clinical Nutrition 104
(6): 1671-1682.
- San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA et
al. (2014). Panobinostat plus bortezomib and dexamethasone
versus placebo plus bortezomib and dexamethasone in patients
with relapsed or relapsed and refractory multiple myeloma:
a multicentre, randomised, double-blind phase 3 trial. The
Lancet Oncology 15 (11): 1195-1206.
- San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA et
al. (2016). Overall survival of patients with relapsed multiple
myeloma treated with panobinostat or placebo plus bortezomib
and dexamethasone (the PANORAMA 1 trial): a randomised,
placebo-controlled, phase 3 trial. The Lancet Haematology 3
(11): e506-e515.
- Sato T, Issa JPJ, Kropf P (2017). DNA hypomethylating drugs in
cancer therapy. Cold Spring Harbor Perspectives in Medicine 7
(5): a026948. doi: 10.1101/cshperspect.a026948.
- Sawada G, Takahashi Y, Niida A, Shimamura T, Kurashige J et al.
(2014). Loss of CDCP1 expression promotes invasiveness and
poor prognosis in esophageal squamous cell carcinoma. Annals
of Surgical Oncology 21 (4): 640-647.
- Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F et al. (2010). A
chromatin-mediated reversible drug-tolerant state in cancer cell
subpopulations. Cell 141 (1): 69-80.
- Sherman EJ, Su YB, Lyall A, Schöder H, Fury MG et al. (2013). Evaluation
of romidepsin for clinical activity and radioactive iodine reuptake
in radioactive iodine–refractory thyroid carcinoma. Thyroid 23
(5): 593-599.
- Shi J, Wang E, Zuber J, Rappaport A, Taylor M et al. (2013). The
Polycomb complex PRC2 supports aberrant self-renewal in a
mouse model of MLL-AF9; Nras G12D acute myeloid leukemia.
Oncogene 32 (7): 930-938.
- Shi Y (2007). Histone lysine demethylases: emerging roles in
development, physiology and disease. Nature Reviews Genetics
8 (11): 829-833.
- Simon JA, Lange CA (2008). Roles of the EZH2 histone methyltransferase
in cancer epigenetics. Mutation Research/Fundamental and
Molecular Mechanisms of Mutagenesis 647 (1-2): 21-29.
- Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G et al.
(2015). Immunomodulatory action of the DNA methyltransferase
inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Epigenetics 10 (3): 237-246.
- Steele N, Finn P, Brown R, Plumb JA (2009). Combined inhibition of
DNA methylation and histone acetylation enhances gene reexpression and drug sensitivity in vivo. British Journal of Cancer
100 (5): 758-763.
- Stockhausen MT, Sjölund J, Manetopoulos C, Axelson H (2005). Effects
of the histone deacetylase inhibitor valproic acid on Notch
signalling in human neuroblastoma cells. British Journal of
Cancer 92 (4): 751-759.
- Sulaiman A, Sulaiman B, Khouri L, McGarry S, Nessim C et al.
(2016). Both bulk and cancer stem cell subpopulations in triple‐
negative breast cancer are susceptible to Wnt, HDAC, and ERα
coinhibition. FEBS Letters 590 (24): 4606-4616.
- Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P et al.
(2009). EZH2 is essential for glioblastoma cancer stem cell
maintenance. Cancer Research 69 (24): 9211-9218.
- Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E et al. (2008). Promoter
hypomethylation regulates CD133 expression in human gliomas.
Cell Research 18 (10): 1037-1046.
- Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara‐Konishi
J et al. (2016). Combined inhibition of EZH 2 and histone
deacetylases as a potential epigenetic therapy for non‐small‐cell
lung cancer cells. Cancer Science 107 (7): 955-962.
- Tammen SA, Friso S, Choi SW (2013). Epigenetics: the link between
nature and nurture. Molecular Aspects of Medicine 34 (4): 753-
764.
- Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN et al. (2012).
Targeting triple-negative breast cancer cells with the histone
deacetylase inhibitor panobinostat. Breast Cancer Research
14(3): R79. doi: 10.1186/bcr3192
- Thaler F (2012). Current trends in the development of histone
deacetylase inhibitors: a review of recent patent applications.
Pharmaceutical Patent Analyst 1 (1): 75-90.
- Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA et al. (2014).
A phase I/II trial of belinostat in combination with cisplatin,
doxorubicin, and cyclophosphamide in thymic epithelial
tumors: a clinical and translational study. Clinical Cancer
Research 20 (21): 5392-5402.
- Tian J, Lee SO, Liang L, Luo J, Huang CK et al. (2012). Targeting
the unique methylation pattern of androgen receptor (AR)
promoter in prostate stem/progenitor cells with 5-aza2′-deoxycytidine (5-AZA) leads to suppressed prostate
tumorigenesis. Journal of Biological Chemistry 287 (47):
39954-39966.
- Toden S, Tran HM, Tovar-Camargo OA, Okugawa Y, Goel A (2016).
Epigallocatechin-3-gallate targets cancer stem-like cells and
enhances 5-fluorouracil chemosensitivity in colorectal cancer.
Oncotarget 7 (13): 16158-16171.
- Toh TB, Lim JJ, Chow EKH (2017). Epigenetics in cancer stem cells.
Molecular Cancer 16 (1): 29. doi: 10.1186/s12943-017-0596-
9.
Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K et al.
(2009). Vorinostat (NSC# 701852) in patients with relapsed
non-small cell lung cancer: a Wisconsin Oncology Network
phase II study. Journal of Thoracic Oncology 4 (4): 522-526.
- Tsai HC, Li H, Van Neste L, Cai Y, Robert C et al. (2012). Transient
low doses of DNA-demethylating agents exert durable
antitumor effects on hematological and epithelial tumor cells.
Cancer Cell 21 (3): 430-446.
- Valentini A, Gravina P, Federici G, Bernardini S (2007). Valproic
acid induces apoptosis, p16INK4A upregulation and
sensitization to chemotherapy in human melanoma cells.
Cancer Biology & Therapy 6 (2): 185-191.
- Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M (2004). Stem
cells and cancer: the polycomb connection. Cell 118 (4): 409-
418.
- van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C et al.
(2013). EZH2 is required for breast and pancreatic cancer
stem cell maintenance and can be used as a functional cancer
stem cell reporter. Stem Cells Translational Medicine 2 (1):
43-52.
- Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL et
al. (2008). Early phase II trial of oral vorinostat in relapsed
or refractory breast, colorectal, or non-small cell lung cancer.
Investigational New Drugs 26 (5): 483-488.
- Vedeld HM, Skotheim RI, Lothe RA, Lind GE (2014). The recently
suggested intestinal cancer stem cell marker DCLK1 is an
epigenetic biomarker for colorectal cancer. Epigenetics 9 (3):
346-350.
- Verma M, Kumar V (2018). Epigenetic drugs for cancer and
precision medicine. In: Moskalev AA, Alexander Vaiserman
A. Epigenetics of Aging and Longevity. New York/London:
Academic Press, pp. 439-451.
- Vijayaraghavalu S, Dermawan JK, Cheriyath V, Labhasetwar V (2012).
Highly synergistic effect of sequential treatment with epigenetic
and anticancer drugs to overcome drug resistance in breast cancer
cells is mediated via activation of p21 gene expression leading to
G2/M cycle arrest. Molecular Pharmaceutics 10 (1): 337-352.
- Viré E, Brenner C, Deplus R, Blanchon L, Fraga M et al. (2006).
The Polycomb group protein EZH2 directly controls DNA
methylation. Nature 439 (7078): 871-874.
- Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JH et al.
(2018). Phase I study of CC-486 alone and in combination
with carboplatin or nab-paclitaxel in patients with relapsed or
refractory solid tumors. Clinical Cancer Research 24 (17): 4072-
4080.
- Wang X, Zhao H, Lv L, Bao L, Wang X et al. (2016). Prognostic
significance of EZH2 expression in non-small cell lung cancer: A
meta-analysis. Scientific Reports 6: 19239.
Wang Y, Cardenas H, Fang F, Condello S, Taverna P et al. (2014).
- Epigenetic targeting of ovarian cancer stem cells. Cancer Research
74 (17): 4922-4936.
- Wei JW, Huang K, Yang C, Kang CS (2017). Non-coding RNAs as
regulators in epigenetics. Oncology Reports 37 (1): 3-9.
Weikert S, Christoph F, Köllermann J, Müller M, Schrader M et al.
(2005). Expression levels of the EZH2 polycomb transcriptional
repressor correlate with aggressiveness and invasive potential of
bladder carcinomas. International Journal of Molecular Medicine
16 (2): 349-353.
- Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A et al. (2010).
Final results from a multicenter, international, pivotal study
of romidepsin in refractory cutaneous T-cell lymphoma. J Clin
Oncol 28 (29): 4485-4491.
- Yamashita AS, da Costa Rosa M, Borodovsky A, Festuccia WT, Chan
T et al. (2018). Demethylation and epigenetic modification
with 5-azacytidine reduces IDH1 mutant glioma growth in
combination with temozolomide. Neuro-Oncology 21 (2): 189-
200.
- Yi JM, Tsai HC, Glöckner SC, Lin S, Ohm JE et al. (2008). Abnormal
DNA methylation of CD133 in colorectal and glioblastoma
tumors. Cancer Research 68 (19): 8094-8103.
- You H, Ding W, Rountree CB (2010). Epigenetic regulation of cancer
stem cell marker CD133 by transforming growth factor‐β.
Hepatology 51 (5): 1635-1644.
- Zhang C, Samanta D, Lu H, Bullen JW, Zhang H et al. (2016). Hypoxia
induces the breast cancer stem cell phenotype by HIF-dependent
and ALKBH5-mediated m6A-demethylation of NANOG mRNA.
Proceedings of the National Academy of Sciences 113 (14):
E2047-E2056.
- Zhang S, Zhao BS, Zhou A, Lin K, Zheng S et al. (2017). m6A
demethylase ALKBH5 maintains tumorigenicity of glioblastoma
stem-like cells by sustaining FOXM1 expression and cell
proliferation program. Cancer Cell 31 (4): 591-606.
- Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y et al. (2005).
Quantitation of HDAC1 mRNA expression in invasive
carcinoma of the breast. Breast Cancer Research and Treatment
94 (1): 11-16.
- Zhao BS, Roundtree IA, He C (2017). Post-transcriptional gene
regulation by mRNA modifications. Nature Reviews Molecular
Cell Biology 18 (1): 31-42.
- Zhou Y, Perez RE, Duan L, Maki CG (2018). DZNep represses Bcl-2
expression and modulates apoptosis sensitivity in response to
Nutlin-3a. Cancer Biology & Therapy 19 (6): 465-474.
- Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG et al.
(2016). BET bromodomain inhibition promotes anti-tumor
immunity by suppressing PD-L1 expression. Cell Reports 16
(11): 2829-2837.
- Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP et al. (2004).
Induction of HDAC2 expression upon loss of APC in colorectal
tumorigenesis. Cancer Cell 5 (5): 455-463.